Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,300
Closed -$1.12M 4054
2021
Q4
$1.12M Buy
4,300
+3,300
+330% +$856K ﹤0.01% 2446
2021
Q3
$264K Buy
+1,000
New +$273K ﹤0.01% 3755
2021
Q1
Sell
-2,500
Closed -$531K 4191
2020
Q4
$531K Buy
+2,500
New +$498K ﹤0.01% 2475
2020
Q3
Sell
-3,900
Closed -$749K 3486
2020
Q2
$749K Sell
3,900
-4,100
-51% -$671K ﹤0.01% 1726
2020
Q1
$1.18M Buy
8,000
+5,000
+167% +$796K 0.01% 1300
2019
Q4
$465K Hold
3,000
﹤0.01% 2854
2019
Q3
$405K Buy
+3,000
New +$393K ﹤0.01% 2720

Other funds holding RMD

John Overdeck's RMD Position: Q2 2026 in Review

John Overdeck increased its ResMed (RMD) stake by 32% in Q2 2026, buying an estimated $20.4M and bringing the position to 411,036 shares worth $80.1M. The position accounts for 0.06% of the portfolio, ranked #384.

John Overdeck first reported a position in RMD in Q2 2013 and has held it in 23 quarters since. The position peaked at $138M in Q3 2023. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • John Overdeck held 411,036 shares of ResMed worth $80.1M as of Q2 2026.
  • John Overdeck bought 98,568 ResMed shares in Q2 2026, an estimated $20.4M.
  • ResMed made up 0.06% of John Overdeck's portfolio in Q2 2026, its #384 holding.
  • John Overdeck first reported a position in ResMed in Q2 2013 and has held it in 23 quarters since.
  • John Overdeck's ResMed position peaked at $138M in Q3 2023.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.